BioPharm International
February 01, 2004
Columns and Departments
17
2
Welcome to the inaugural issue of the new BioPharm International. We are pleased to unveil our new logo and redesign after collaborating for four months with award-winning designer Virginia Dickens of Vision Advertising. One of our redesign goals was for the magazine to reflect the same innovative, cutting-edge qualities that are characteristic of the evolving biopharm industry. Probably more important to you is how the new format will better accommodate the expression of your day-to-day challenges.
February 01, 2004
Site Expansion
17
2
Regional Round-Up: Virginia
February 01, 2004
Risk Reduction
17
2
This article focuses on the front end of qualifying a new raw material from a given supplier. Once qualified, this status must be maintained by periodic review and requalification.
February 01, 2004
Columns and Departments
17
2
Current productivity initiatives may be too little, too late ? a more drastic overhaul may be required.
February 01, 2004
Risk Reduction
17
2
Operational planning and early cost analyses are key to generating optimal, robust, and economical commercial processes.
February 01, 2004
International BioMarket
17
2
Canada's biotechnology industry has expanded rapidly in the last decade, as measured by industry-wide revenues, the launch of new companies, and the continuous diversification of its products.
February 01, 2004
Columns and Departments
17
2
On Wall Street, accurately predicting the future is the Holy Grail. At the end of the day, the traders and investors who come closest to guessing what will happen one hour, one day, or one week down the road are the ones who go home winners.
February 01, 2004
International BioMarket
17
2
Biotech patent decisions before the Supreme Court and the Prime Minister's commitment to innovation will shape the future of life sciences protection in Canada.
February 01, 2004
Site Expansion
17
2
Regional Round-Up: Maryland
February 01, 0004
Columns and Departments
17
2
FDA expands electronic data submission programs to improve regulatory operations and ensure appropriate and safe drug use.